# Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

> **NCT03789240** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Follicular Lymphoma
- Non-Hodgkin's Lymphoma
- NHL

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Copanlisib
- **PROCEDURE:** Bone Marrow Aspiration/Biopsy
- **DIAGNOSTIC_TEST:** CT Scans
- **DIAGNOSTIC_TEST:** 18F-FDG-PET/CT Scan15
- **DIAGNOSTIC_TEST:** Electrocardigram

## Key facts

- **NCT ID:** NCT03789240
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-22
- **Primary completion:** 2025-09-24
- **Final completion:** 2027-01-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789240, "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03789240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*